Prolia injection contains denosumab as its active ingredient.
Denosumab is a monoclonal antibody that specifically targets RANKL (receptor activator of nuclear factor kappa-B ligand). RANKL is a protein that regulates the formation, function, and survival of osteoclasts, which are cells responsible for breaking down bone. By binding to RANKL, denosumab inhibits osteoclast activity, thereby decreasing bone resorption and increasing bone density.
In simpler terms, Prolia (denosumab) helps to reduce bone loss, making bones stronger and less likely to fracture. It does this by blocking a substance in the body that causes bone breakdown.
Prolia also contains inactive ingredients. While these may vary slightly depending on the manufacturer and batch, common inactive ingredients include:
- Sorbitol: A sweetener and stabilizer.
- Polysorbate 20: A surfactant to help stabilize the solution.
- Acetic acid glacial: Used to adjust the pH.
- Sodium hydroxide: Also used to adjust the pH.
- Water for injection: As a solvent.
It is crucial to note that people with allergies or sensitivities to any of these ingredients should inform their healthcare provider before receiving a Prolia injection.
